1.1 Normal Growth, Development & Growth-Chart Interpretation
Key Takeaways
- The WHO growth standards are used from birth to age 24 months and the CDC growth charts from age 2 years onward; preterm infants are plotted on a preterm chart such as Fenton until about 50 weeks post-menstrual age and thereafter on corrected age, conventionally through 24 months for weight, 18 months for head circumference, and up to 36 to 40 months for length.
- Term infants lose 5% to 10% of birth weight in the first days of life and regain it by 10 to 14 days, double birth weight by 4 to 6 months, triple it by 12 months, and grow about 25 cm in length and 12 cm in head circumference during the first year.
- CDC BMI-for-age categories are underweight below the 5th percentile, healthy weight 5th to below 85th, overweight 85th to below 95th, class 1 obesity from the 95th percentile to below 120% of it, class 2 severe obesity at 120% to below 140% of the 95th percentile or BMI 35 kg/m2, and class 3 at 140% or BMI 40 kg/m2, with the December 2022 CDC extended charts providing the curves needed to plot above the 97th percentile.
- Crossing two or more major percentile channels downward, or weight-for-length or BMI below the 5th percentile, defines faltering growth and should trigger a medication review for appetite-suppressing stimulants, growth-suppressing inhaled corticosteroids, and drug-induced malabsorption.
- Sexual Maturity Rating (Tanner) stage 2 marks the onset of puberty and the point at which body composition, hepatic enzyme activity, and renal clearance begin diverging by sex, so a child at the same weight may need a different mg/kg dose before and after this transition.
1.1 Normal Growth, Development & Growth-Chart Interpretation
A pediatric pharmacist reads a growth chart the way an adult pharmacist reads a serum creatinine trend: it is a longitudinal physiologic signal, not a single data point. Almost every pediatric dose is anchored to weight, length, or body surface area, so the accuracy of a dose depends on the accuracy and the interpretation of an anthropometric measurement. Growth data also serve as a pharmacovigilance instrument — inhaled corticosteroids, stimulants, systemic glucocorticoids, and several antiretrovirals all announce toxicity as a change in growth trajectory long before a laboratory value moves.
Growth refers to a measurable increase in body size. Development refers to the progressive acquisition of function — motor, cognitive, language, and social. The two are tracked separately and have different pharmacy consequences: growth drives the dose, development drives the dosage form and the device.
Which Chart, and When
| Population | Chart | Range | Notes |
|---|---|---|---|
| Birth to 24 months (term) | WHO Growth Standards | 0–24 mo | Prescriptive: describes how healthy, predominantly breastfed children should grow. CDC and AAP recommend these below age 2. |
| 2 through 19 years | CDC Growth Charts | 2–20 yr | Descriptive: derived from US survey data (NHANES). Includes BMI-for-age. |
| BMI above the 97th percentile | CDC Extended BMI-for-age Charts (released December 2022) | 2–20 yr | The 2000 charts flatten above the 95th percentile and cannot distinguish a child at the 96th from one at the 99.9th. The extended charts add the 98th, 99th, 99.9th, and 99.99th curves and plot BMI to 60 kg/m². |
| Preterm infants | Fenton (or INTERGROWTH-21st) preterm charts | 22–50 wk PMA | Plotted by post-menstrual age until roughly 50 weeks PMA, then transitioned to the WHO chart using corrected age. |
| Down syndrome, Turner syndrome, achondroplasia, cerebral palsy | Syndrome-specific charts | varies | Used alongside, never instead of, the standard chart. |
[!IMPORTANT] The chart switch at age 2 is not cosmetic. WHO standards describe a breastfed reference population that gains weight more slowly after 3 months than the CDC descriptive population. A toddler who appears to be "dropping percentiles" across the 24-month transition may simply have moved from one reference population to another. Confirm the chart before concluding that growth has faltered.
Correcting for Prematurity
Corrected (adjusted) age = chronological age − (40 weeks − gestational age at birth). Conventional correction windows are:
- Head circumference: correct through 18 months
- Weight: correct through 24 months
- Length/height: correct through 36 to 40 months
An infant born at 28 weeks who is now 9 months old chronologically has a corrected age of 9 months − 12 weeks = 6 months. Plotting that infant at 9 months manufactures a false diagnosis of growth failure and can trigger an unnecessary nutrition or endocrine workup.
Growth Velocity Benchmarks Worth Memorizing
FIRST YEAR OF LIFE — EXPECTED TRAJECTORY
WEIGHT Birth ........ physiologic loss of 5-10% over 3-5 days
Day 10-14 .... back to birth weight
Month 4-6 .... DOUBLE birth weight
Month 12 ..... TRIPLE birth weight
Month 24 ..... QUADRUPLE birth weight
DAILY 0-3 mo ....... 20-30 g/day
GAIN 3-6 mo ....... 15-20 g/day
6-12 mo ...... 10-15 g/day
LENGTH Birth ~50 cm -> ~75 cm at 12 months (+50%)
Doubles birth length by ~4 years
HEAD Birth ~35 cm; +2 cm/mo (mo 1-3), +1 cm/mo (mo 4-6),
CIRCUM. +0.5 cm/mo (mo 7-12) => ~47 cm at 12 months
After infancy, growth slows to roughly 2 kg and 5 to 7 cm per year through mid-childhood, then accelerates sharply at the pubertal growth spurt. Girls peak in height velocity at about 8 to 9 cm/year around Tanner stage 3; boys peak later and higher, at about 9 to 10 cm/year around Tanner stages 3 to 4.
Percentiles, Channels, and Z-Scores
A percentile states the rank of a measurement within the reference population; a z-score states how many standard deviations the measurement sits from the median. Z-scores are preferred in nutrition support and research because they remain discriminating at the extremes, where percentiles compress — the difference between the 0.1st and the 2nd percentile is large physiologically but invisible on a percentile scale.
Major percentile lines (3rd, 5th, 10th, 25th, 50th, 75th, 90th, 95th, 97th) define channels. The clinically meaningful signal is not which channel a child occupies but whether they stay in it.
BMI-for-age obesity severity (CDC, carried into the AAP 2023 obesity clinical practice guideline):
| Category | Threshold |
|---|---|
| Underweight | BMI $<$ 5th percentile |
| Healthy weight | 5th to $<$ 85th percentile |
| Overweight | 85th to $<$ 95th percentile |
| Obesity, class 1 | 95th percentile to $<120%$ of the 95th percentile |
| Obesity, class 2 (severe) | $120%$ to $<140%$ of the 95th percentile, or BMI $\ge 35$ kg/m², whichever is lower |
| Obesity, class 3 | $\ge 140%$ of the 95th percentile, or BMI $\ge 40$ kg/m², whichever is lower |
- Faltering growth (failure to thrive): weight-for-age or weight-for-length below the 5th percentile, or a sustained downward crossing of two or more major percentile channels.
- Normal channel shifts: most healthy infants shift channels once during the first 18 months as they regress toward their genetically determined trajectory. A single crossing in this window, with normal linear growth and development, is usually benign.
- Red flag ordering: weight falls first, then length, then head circumference. Head circumference falling first points away from undernutrition and toward a primary neurologic or genetic cause.
Medication Review Triggered by Growth Faltering
| Drug class | Growth effect | Pharmacist action |
|---|---|---|
| Stimulants (methylphenidate, amphetamines) | Appetite suppression; average height deficit roughly 1–2 cm with sustained use | Plot height and weight every 6 months; consider dose timing, calorie-dense evening meals, or a planned drug holiday |
| Inhaled corticosteroids | Roughly 0.5–1 cm reduction in first-year growth velocity; small effect on adult height | Stadiometer height every 3–6 months; step down to the lowest effective dose after 3 months of control |
| Systemic glucocorticoids | Marked growth suppression, dose- and duration-dependent | Push alternate-day or inhaled/topical routes; monitor for adrenal suppression |
| Topiramate, stimulant-class appetite suppressants | Anorexia, weight loss | Reassess necessity; dietitian referral |
| Proton pump inhibitors, orlistat, cholestyramine | Micronutrient or fat-soluble vitamin malabsorption | Supplement and monitor vitamins A, D, E, K |
Development: What It Changes About the Prescription
Developmental stage, not age alone, determines whether a child can physically take a medication. The CDC and AAP revised the developmental-milestone checklists in February 2022 so that each listed milestone is one achieved by about 75% of children at that age, making a missed milestone a more actionable prompt for referral.
| Stage | Representative milestones | Pharmacy consequence |
|---|---|---|
| Neonate/infant (0–12 mo) | Head control ~4 mo; sits ~6 mo; pincer grasp ~9 mo | Oral liquids only, given by oral syringe into the buccal pocket. No honey before 12 months (infant botulism). Hyperosmolar liquids risk necrotizing enterocolitis in preterm infants. |
| Toddler (1–3 yr) | Walks ~12 mo; two-word phrases ~24 mo; negativism peaks | Liquids and orodispersible or chewable forms from about age 2. Expect refusal; taste-masking and caregiver coaching matter more than potency. |
| Preschool (3–5 yr) | Magical thinking; fears bodily harm | Most children cannot reliably swallow intact tablets before about 6 years, though structured pill-swallowing training succeeds in many from age 4. Metered-dose inhaler requires a valved holding chamber with a face mask. |
| School age (6–11 yr) | Concrete operational reasoning; wants to participate | Tablets and capsules usually feasible. Spacer with mouthpiece replaces the mask (about age 4–5). Dry powder inhalers require sustained high inspiratory flow and are generally reserved for age 5 to 6 and older. |
| Adolescent (12–18 yr) | Abstract reasoning; autonomy-seeking; risk-taking | Counsel the adolescent directly, confidentially where law allows. Adherence, not formulation, becomes the rate-limiting problem. |
Sexual Maturity Rating and Its Pharmacokinetic Consequences
Tanner (Sexual Maturity Rating) staging runs 1 through 5 for breast/genital development and pubic hair.
- SMR 1: prepubertal.
- SMR 2: onset of puberty — breast budding in girls (average age about 10–11 years) and testicular volume above 4 mL in boys (average about 11–12 years).
- SMR 5: adult.
Puberty is a pharmacokinetic inflection point. Lean body mass and total body water rise steeply in boys while fat mass rises in girls, so volumes of distribution for hydrophilic and lipophilic drugs diverge by sex for the first time. CYP3A4 and CYP1A2 activity, which exceed adult levels through childhood on a per-kilogram basis, decline toward adult values. Insulin requirements in type 1 diabetes surge to 1.0 to 1.5 units/kg/day at SMR 2 through 4 and fall again once linear growth stops. Appearance of SMR 2 changes before age 8 in girls or age 9 in boys defines precocious puberty and triggers an evaluation, not a dose adjustment.
Practice Pearls & BCPPS Exam Traps
- Exam Trap 1: A 26-week preterm infant at 4 months chronological age plotted on the WHO chart appears far below the 3rd percentile. The correct action is to correct for prematurity, not to escalate nutrition support.
- Exam Trap 2: Length is measured recumbent below age 2 and standing height from age 2 onward using a wall-mounted stadiometer. Recumbent length exceeds standing height by roughly 0.7 cm; switching methods without switching charts manufactures an artificial drop in the growth curve.
- Exam Trap 3: Weight-for-length, not BMI, is the correct adiposity index below age 2. BMI-for-age is only validated from age 2.
- Board Rule: Before attributing growth faltering in a child with asthma to the disease, confirm that the inhaled corticosteroid is at the lowest effective step, that the child is using a valved holding chamber, and that height is measured by stadiometer rather than estimated.
An infant born at 30 weeks gestational age is brought to the pediatric clinic at a chronological age of 7 months. The parent is alarmed that the infant's weight plots below the 3rd percentile on the WHO growth standard. The infant is feeding well, has normal stool output, and is meeting motor milestones for a 4- to 5-month-old. Which action by the pediatric clinical pharmacist is most appropriate?
A 9-year-old child with persistent asthma has received medium-dose inhaled fluticasone for 18 months. Serial stadiometer heights show the child has fallen from the 50th percentile to the 25th percentile, while weight-for-age is unchanged at the 55th percentile and asthma has been fully controlled for the past 8 months. Which interpretation and action are most appropriate?
A pediatric clinical pharmacist is selecting an asthma controller delivery device for a healthy 3-year-old who has been prescribed a metered-dose inhaler. Which device recommendation is developmentally appropriate?